Zevra Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Zevra Therapeutics
ZVRA Stock   8.50  0.10  1.19%   
Zevra Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Zevra Therapeutics' valuation are provided below:
Gross Profit
68.1 M
Profit Margin
0.4186
Market Capitalization
472.9 M
Enterprise Value Revenue
3.9829
Revenue
84.4 M
We have found one hundred twenty available fundamental gauges for Zevra Therapeutics, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of Zevra Therapeutics prevalent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 364.5 M. The current year's Enterprise Value is expected to grow to about 389.6 M

Zevra Therapeutics Total Revenue

21.27 Million

Check Zevra Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zevra Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.7 M, Selling General Administrative of 66.3 M or Other Operating Expenses of 133.6 M, as well as many indicators such as Price To Sales Ratio of 15.44, Dividend Yield of 0.0 or PTB Ratio of 9.19. Zevra financial statements analysis is a perfect complement when working with Zevra Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Zevra Stock
Check out the analysis of Zevra Therapeutics Correlation against competitors.
For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.

Zevra Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets215.1 M204.8 M75.6 M
Slightly volatile
Short and Long Term Debt Total49.8 M69.3 M41.6 M
Slightly volatile
Other Current Liabilities4.8 M7.1 M4.2 M
Slightly volatile
Total Current Liabilities41.1 M39.2 M15.8 M
Slightly volatile
Property Plant And Equipment Net1.6 M1.2 M1.3 M
Slightly volatile
Accounts Payable15.8 M15 M4.4 M
Slightly volatile
Cash30.1 M38.9 M25.2 M
Slightly volatile
Non Current Assets Total111.2 M105.9 M27.5 M
Slightly volatile
Other Assets468.8 K832.6 K473.5 K
Slightly volatile
Cash And Short Term Investments45.5 M79.9 M39.3 M
Slightly volatile
Net Receivables12.7 M12.1 M4.5 M
Slightly volatile
Common Stock Shares Outstanding55.8 M53.2 M15.6 M
Slightly volatile
Liabilities And Stockholders Equity215.1 M204.8 M75.6 M
Slightly volatile
Non Current Liabilities Total60.1 M120.1 M52.4 M
Slightly volatile
Total Liabilities167.2 M159.2 M72.5 M
Slightly volatile
Total Current Assets51.5 M98.9 M45 M
Slightly volatile
Short Term Debt458.9 K483 K3.6 M
Pretty Stable
Common Stock4.3 K4.5 K317.2 K
Slightly volatile
Current Deferred Revenue5.6 M9.5 M5.9 M
Pretty Stable
Other Liabilities5.3 M5 M1.5 M
Slightly volatile
Long Term Debt35.6 M53.6 M60 M
Slightly volatile
Capital Lease Obligations1.2 M712.8 K1.8 M
Slightly volatile
Net Invested Capital79.6 M114 M38.5 M
Slightly volatile
Property Plant And Equipment Gross2.8 M3.1 M2.8 M
Slightly volatile
Non Current Liabilities Other14.8 M14.1 M3.7 M
Slightly volatile
Net Working Capital47.5 M59.8 M22.2 M
Slightly volatile
Property Plant Equipment1.8 M1.6 M2.5 M
Slightly volatile
Short and Long Term Debt45.5 M43.4 M10.5 M
Slightly volatile
Intangible Assets55.3 M62.1 M68 M
Slightly volatile

Zevra Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.7 M7.3 M1.5 M
Slightly volatile
Selling General Administrative66.3 M63.1 M18.4 M
Slightly volatile
Other Operating Expenses133.6 M127.2 M43.6 M
Slightly volatile
Research Development50.8 M48.4 M21.2 M
Slightly volatile
Total Operating Expenses124.6 M118.7 M41.5 M
Slightly volatile
Interest Expense4.6 M8.5 M3.8 M
Slightly volatile
Selling And Marketing Expenses368.3 K350.8 K221.7 K
Slightly volatile
Cost Of Revenue9 M8.5 M2.1 M
Slightly volatile
Interest Income1.5 M2.5 M880.8 K
Slightly volatile
Total Revenue21.3 M27.2 M16.5 M
Slightly volatile
Reconciled Depreciation7.7 M7.3 M1.6 M
Slightly volatile

Zevra Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation18 M17.1 M5.4 M
Slightly volatile
Depreciation7.7 M7.3 M1.5 M
Slightly volatile
End Period Cash Flow30.2 M38.9 M25.4 M
Slightly volatile
Begin Period Cash Flow29.8 M49.5 M24.2 M
Slightly volatile
Issuance Of Capital Stock77.9 M74.2 M22.7 M
Slightly volatile
Change To Netincome14.6 M25.7 M10.1 M
Slightly volatile
Dividends Paid277 K291.6 K21.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio15.4414.75.3924
Slightly volatile
Days Sales Outstanding11114692.3271
Slightly volatile
Average Payables470.8 K885.6 K761.9 K
Slightly volatile
Stock Based Compensation To Revenue0.60.570.3616
Slightly volatile
Capex To Depreciation0.320.340.5968
Pretty Stable
EV To Sales16.515.718.874
Slightly volatile
Inventory Turnover3.563.390.7462
Slightly volatile
Days Of Inventory On Hand1061112.2 K
Slightly volatile
Payables Turnover0.740.510.6348
Slightly volatile
Sales General And Administrative To Revenue1.431.360.9791
Slightly volatile
Research And Ddevelopement To Revenue1.031.61.409
Pretty Stable
Capex To Revenue0.01020.00970.0045
Slightly volatile
Cash Per Share1.641.7319.7382
Slightly volatile
Days Payables Outstanding7037403 K
Slightly volatile
Intangibles To Total Assets0.460.480.4329
Slightly volatile
Current Ratio4.32.274.7744
Pretty Stable
Receivables Turnover2.452.586.0486
Slightly volatile
Capex Per Share0.00910.00960.1075
Slightly volatile
Average Receivables959 K1.1 M1.2 M
Slightly volatile
Revenue Per Share0.560.594.4883
Slightly volatile
Interest Debt Per Share1.61.6827.3614
Pretty Stable
Debt To Assets0.290.31.4514
Very volatile
Operating Cycle2222331.2 K
Slightly volatile
Days Of Payables Outstanding7037403 K
Slightly volatile
Quick Ratio4.272.224.7373
Pretty Stable
Net Income Per E B T0.781.050.9485
Slightly volatile
Cash Ratio0.850.893.2401
Very volatile
Days Of Inventory Outstanding1061112.2 K
Slightly volatile
Days Of Sales Outstanding11114692.3271
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.161.0214
Slightly volatile
Fixed Asset Turnover22.0320.988.9653
Slightly volatile
Debt Ratio0.290.31.4514
Very volatile
Price Sales Ratio15.4414.75.3924
Slightly volatile
Asset Turnover0.140.150.8406
Slightly volatile
Gross Profit Margin0.950.790.8137
Slightly volatile

Zevra Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap364.5 M347.2 M175.7 M
Slightly volatile
Enterprise Value389.6 M371 M187.4 M
Slightly volatile

Zevra Fundamental Market Drivers

Forward Price Earnings14.245
Cash And Short Term Investments69.5 M

Zevra Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Zevra Therapeutics Financial Statements

Zevra Therapeutics stakeholders use historical fundamental indicators, such as Zevra Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Zevra Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Zevra Therapeutics' assets and liabilities are reflected in the revenues and expenses on Zevra Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Zevra Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9.5 M5.6 M
Cost Of Revenue8.5 M9 M
Total Revenue27.2 M21.3 M
Stock Based Compensation To Revenue 0.57  0.60 
Sales General And Administrative To Revenue 1.36  1.43 
Research And Ddevelopement To Revenue 1.60  1.03 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.59  0.56 
Ebit Per Revenue(4.24)(4.03)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock:
How To Invest In Zevra
Details
Is Zevra Stock a good investment?
Details
What is Zevra Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Zevra Therapeutics Correlation against competitors.
For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. Anticipated expansion of Zevra directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Zevra Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
0.47
Revenue Per Share
1.546
Quarterly Revenue Growth
6.054
Return On Assets
(0.08)
Return On Equity
0.3481
Understanding Zevra Therapeutics requires distinguishing between market price and book value, where the latter reflects Zevra's accounting equity. The concept of intrinsic value - what Zevra Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Zevra Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Zevra Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY